PubRank

Jeffrey S Weber

Author PubWeight™ 178.93‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010 67.34
2 Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009 24.11
3 Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013 18.08
4 Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012 13.17
5 Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med 2003 3.60
6 BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol 2011 2.87
7 Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int Immunol 2007 2.67
8 Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol 2013 2.51
9 The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res 2012 2.31
10 Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol 2013 2.11
11 A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs 2010 2.09
12 Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun 2010 2.07
13 Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci 2013 2.03
14 T-cell therapy at the threshold. Nat Biotechnol 2012 1.91
15 Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist 2013 1.91
16 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci Rep 2012 1.81
17 Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol 2008 1.60
18 Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin Cancer Res 2010 1.54
19 Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function. J Immunother 2011 1.46
20 Marked differences in human melanoma antigen-specific T cell responsiveness after vaccination using a functional microarray. PLoS Med 2005 1.42
21 Diversity and recognition efficiency of T cell responses to cancer. PLoS Med 2004 1.36
22 CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues. Ann Surg Oncol 2008 1.28
23 Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res 2010 1.19
24 Recent advances using anti-CTLA-4 for the treatment of melanoma. Cancer J 2009 1.19
25 Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma. Cancer 2003 1.08
26 c-KIT signaling as the driving oncogenic event in sub-groups of melanomas. Histol Histopathol 2009 1.08
27 Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery. Int J Radiat Oncol Biol Phys 2002 1.07
28 Biomarkers on melanoma patient T cells associated with ipilimumab treatment. J Transl Med 2012 1.04
29 Intra-lymph node prime-boost vaccination against Melan A and tyrosinase for the treatment of metastatic melanoma: results of a phase 1 clinical trial. Clin Cancer Res 2011 1.04
30 Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. Clin Cancer Res 2013 1.04
31 Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma. J Clin Oncol 2009 1.01
32 Making dendritic cells from the inside out: lentiviral vector-mediated gene delivery of granulocyte-macrophage colony-stimulating factor and interleukin 4 into CD14+ monocytes generates dendritic cells in vitro. Hum Gene Ther 2004 0.98
33 Review of the clinical experience with 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumors. Curr Opin Investig Drugs 2002 0.97
34 Immune regulatory antibodies: are they the next advance? Cancer J 2010 0.97
35 Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial. J Immunother 2012 0.94
36 Current developments of immunotherapy in the clinic. Curr Opin Immunol 2004 0.94
37 Potent maturation of monocyte-derived dendritic cells after CD40L lentiviral gene delivery. J Immunother 2003 0.93
38 Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512. PLoS One 2012 0.92
39 A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma. Clin Cancer Res 2003 0.88
40 Peptide-based vaccines for cancer immunotherapy. Expert Opin Biol Ther 2004 0.86
41 Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with Stage IV melanoma. Cancer 2006 0.85
42 Therapeutic vaccination for HPV induced cervical cancers. Dis Markers 2007 0.85
43 Immunological consequences of using three different clinical/laboratory techniques of emulsifying peptide-based vaccines in incomplete Freund's adjuvant. J Transl Med 2006 0.84
44 A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma. Invest New Drugs 2006 0.83
45 LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases. J Neurooncol 2014 0.83
46 Immunotherapy of cancer: key findings and commentary on the third Tegernsee conference. Oncologist 2010 0.82
47 Cytotoxic T lymphocyte responses against melanocytes and melanoma. J Transl Med 2011 0.81
48 Large-scale monocyte enrichment coupled with a closed culture system for the generation of human dendritic cells. J Immunol Methods 2002 0.80
49 Expanding targeted therapy to NRAS-mutated melanoma. Lancet Oncol 2013 0.78
50 Up close and personal: the challenges of precision medicine in melanoma. J Natl Cancer Inst 2014 0.78
51 Peptide vaccine trials for melanoma: preclinical background and clinical results. Semin Cancer Biol 2003 0.77
52 Tumor regression and autoimmunity in cytotoxic T lymphocyte-associated antigen 4 blockade-treated patients. Ann Surg Oncol 2005 0.77
53 Taming the wild-types: targeting PAK1 in melanomas that lack BRAF mutations. J Natl Cancer Inst 2013 0.77
54 T-cell activation and maturation at tumor site associated with objective response to ipilimumab in metastatic melanoma. J Clin Oncol 2011 0.76
55 Translation of cancer immunotherapies. Nat Med 2004 0.75
56 Resection of Gastrointestinal Metastases in Stage IV Melanoma: Correlation with Outcomes. Am Surg 2016 0.75
57 Melanoma: promising new discoveries and treatment modalities for difficult clinical scenarios - part II. Cancer Control 2009 0.75
58 Clinical trials in cervical intraepithelial neoplasia: balancing the need for efficacy data with patient safety. J Low Genit Tract Dis 2002 0.75
59 Resection of Gastrointestinal Metastases in Stage IV Melanoma: Correlation with Outcomes. Am Surg 2016 0.75
60 From the guest editor: introduction for immunotherapy of cancer. Cancer J 2010 0.75
61 BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy. Melanoma Res 2016 0.75